Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline

Keyur Patel; Sumeet K. Asrani; Maria Isabel Fiel; Deborah A. Levine; Daniel H. Leung; Andrés Duarte‐Rojo; Jonathan A. Dranoff; Tarek Nayfeh; Bashar Hasan; Tamar H. Taddei; Yahya Alsawaf; Samer Saadi; Abdul M. Majzoub; Apostolos Manolopoulos; Muayad Alzuabi; Jingyi Ding; Nigar Sofiyeva; M. Hassan Murad; Mouaz Alsawas; Don C. Rockey; Richard K. Sterling

doi:10.1097/hep.0000000000000842

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Patel et al. (2024) studied this question.

synapsesocial.com/papers/69d94bd626e251a01968414b https://doi.org/10.1097/hep.0000000000000842

View at Publisher

Ask AI

Bookmark

Share

Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline

Ask about this paper

Abstract

Discussion

Cite This Study

Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading